Related Experiment Video
Updated: Feb 1, 2026

Assaying DNA Damage in Hippocampal Neurons Using the Comet Assay
Published on: December 19, 2012
SMAD3 silencing enhances DNA damage in radiation therapy by interacting with MRE11-RAD50-NBS1 complex in glioma
Zheng Jiang1, Yan Guo2, Lifeng Miao3
1Department of Neurosurgery, Qilu Hospital of Shandong University, No. 107 Wenhua West Road, Lixia District, Jinan, Shandong Province, P. R. China.
Abstract:
Radiotherapy is the major treatment modality for malignant glioma. However, the treatment response of radiotherapy is suboptimal due to resistance. Here we aimed to explore the effect and mechanism of Mothers against decapentaplegic homologue (SMAD3) silencing in sensitizing malignant glioma to radiotherapy. Clonogenic assay was used to evaluate the sensitivity of glioma cells to increasing doses of radiation. Glioma cells were transfected with small-interfering RNAs (siRNAs) specific to SMAD3. Overexpression of SMAD3 was achieved by transfecting expression plasmid encoding SMAD3 cDNA. Changes in MRE11-RAD50-NBS1 mRNA and protein levels were assessed through qPCR analysis and western blot analysis, respectively. Chromatin immunoprecipitation (ChIP) was used to confirm the interaction between SMAD3 and MRE11-RAD50-NBS1 (MRN) complex. Silencing of SMAD3 increased sensitivity of glioma cells to radiotherapy. MRE11, RAD50 and NBS1 were overexpressed in response to radiotherapy, which was attenuated by SMAD3 silencing while boosted by SMAD3 overexpression. ChIP analysis confirmed the interaction of SMAD3 with MRE11, RAD50 and NBS1 under radiotherapy, which was inhibited by SMAD3 silencing. SMAD3 silencing is an effective strategy for sensitizing glioma to radiotherapy, which is mediated by the interaction of SMAD3 with the MRN complex.
Insights
Silencing Mothers against decapentaplegic homologue 3 (SMAD3) enhances radiotherapy effectiveness in malignant glioma. This occurs by SMAD3 silencing inhibiting the MRE11-RAD50-NBS1 complex, improving treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Radiotherapy is a primary treatment for malignant glioma, but resistance limits its efficacy.
- Understanding molecular mechanisms of radioresistance is crucial for improving glioma treatment outcomes.
Purpose of the Study:
- To investigate the role of Mothers against decapentaplegic homologue 3 (SMAD3) in modulating malignant glioma response to radiotherapy.
- To elucidate the mechanism by which SMAD3 influences glioma radioresistance.
Main Methods:
- Malignant glioma cells were treated with small-interfering RNAs (siRNAs) targeting SMAD3 or SMAD3 expression plasmids.
- Cell sensitivity to radiation was assessed using clonogenic assays.
- MRE11-RAD50-NBS1 (MRN) complex mRNA and protein levels were quantified via qPCR and Western blot.
- Chromatin immunoprecipitation (ChIP) assays were employed to confirm SMAD3 interaction with the MRN complex.
Main Results:
- SMAD3 silencing significantly increased the sensitivity of glioma cells to radiotherapy.
- Radiotherapy-induced overexpression of MRE11, RAD50, and NBS1 was attenuated by SMAD3 silencing and enhanced by SMAD3 overexpression.
- ChIP analysis confirmed that SMAD3 interacts with the MRN complex under radiotherapy conditions, and this interaction is inhibited by SMAD3 silencing.
Conclusions:
- SMAD3 silencing is a viable strategy to enhance radiotherapy efficacy in malignant glioma.
- The mechanism involves SMAD3 interaction with the MRE11-RAD50-NBS1 complex, modulating the cellular response to radiation.
Related Concept Videos
Interaction of EM Radiation with Matter: Spectroscopy
Biological Effects of Radiation
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
piRNA - Piwi-interacting RNAs
Overview of DNA Repair
Chemically...

